422 related articles for article (PubMed ID: 30234288)
1. Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides.
Nunes R; Araújo F; Barreiros L; Bártolo I; Segundo MA; Taveira N; Sarmento B; das Neves J
ACS Appl Mater Interfaces; 2018 Oct; 10(41):34942-34953. PubMed ID: 30234288
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs.
Cunha-Reis C; Machado A; Barreiros L; Araújo F; Nunes R; Seabra V; Ferreira D; Segundo MA; Sarmento B; das Neves J
J Control Release; 2016 Dec; 243():43-53. PubMed ID: 27664327
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
Date AA; Shibata A; Goede M; Sanford B; La Bruzzo K; Belshan M; Destache CJ
Antiviral Res; 2012 Dec; 96(3):430-6. PubMed ID: 23041201
[TBL] [Abstract][Full Text] [Related]
4. Colorectal distribution and retention of polymeric nanoparticles following incorporation into a thermosensitive enema.
Melo M; Nunes R; Sarmento B; das Neves J
Biomater Sci; 2019 Sep; 7(9):3801-3811. PubMed ID: 31237275
[TBL] [Abstract][Full Text] [Related]
5. [Transport of PLGA nanoparticles across Caco-2/HT29-MTX co-cultured cells].
Wen Z; Li G; Lin DH; Wang JT; Qin LF; Guo GP
Yao Xue Xue Bao; 2013 Dec; 48(12):1829-35. PubMed ID: 24689242
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
7. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system.
Machado A; Cunha-Reis C; Araújo F; Nunes R; Seabra V; Ferreira D; das Neves J; Sarmento B
Acta Biomater; 2016 Oct; 44():332-40. PubMed ID: 27544812
[TBL] [Abstract][Full Text] [Related]
8. Preparation, in vitro and in vivo evaluation of mPEG-PLGA nanoparticles co-loaded with syringopicroside and hydroxytyrosol.
Guan Q; Sun S; Li X; Lv S; Xu T; Sun J; Feng W; Zhang L; Li Y
J Mater Sci Mater Med; 2016 Feb; 27(2):24. PubMed ID: 26704541
[TBL] [Abstract][Full Text] [Related]
9. Preferential tumor accumulation and desirable interstitial penetration of poly(lactic-co-glycolic acid) nanoparticles with dual coating of chitosan oligosaccharide and polyethylene glycol-poly(D,L-lactic acid).
Wang G; Chen Y; Wang P; Wang Y; Hong H; Li Y; Qian J; Yuan Y; Yu B; Liu C
Acta Biomater; 2016 Jan; 29():248-260. PubMed ID: 26476340
[TBL] [Abstract][Full Text] [Related]
10. Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy.
Martins C; Araújo F; Gomes MJ; Fernandes C; Nunes R; Li W; Santos HA; Borges F; Sarmento B
Eur J Pharm Biopharm; 2019 May; 138():111-124. PubMed ID: 29397261
[TBL] [Abstract][Full Text] [Related]
11. Precise engineering of dapivirine-loaded nanoparticles for the development of anti-HIV vaginal microbicides.
das Neves J; Sarmento B
Acta Biomater; 2015 May; 18():77-87. PubMed ID: 25700657
[TBL] [Abstract][Full Text] [Related]
12. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.
Destache CJ; Belgum T; Christensen K; Shibata A; Sharma A; Dash A
BMC Infect Dis; 2009 Dec; 9():198. PubMed ID: 20003214
[TBL] [Abstract][Full Text] [Related]
13. In vitro and ex vivo evaluation of polymeric nanoparticles for vaginal and rectal delivery of the anti-HIV drug dapivirine.
das Neves J; Araújo F; Andrade F; Michiels J; Ariën KK; Vanham G; Amiji M; Bahia MF; Sarmento B
Mol Pharm; 2013 Jul; 10(7):2793-807. PubMed ID: 23738946
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
Lin TsT; Gao DY; Liu YC; Sung YC; Wan D; Liu JY; Chiang T; Wang L; Chen Y
J Control Release; 2016 Jan; 221():62-70. PubMed ID: 26551344
[TBL] [Abstract][Full Text] [Related]
15. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization.
Sánchez-López E; Ettcheto M; Egea MA; Espina M; Cano A; Calpena AC; Camins A; Carmona N; Silva AM; Souto EB; García ML
J Nanobiotechnology; 2018 Mar; 16(1):32. PubMed ID: 29587747
[TBL] [Abstract][Full Text] [Related]
16. Preparation, evaluation, and
Pan X; Liu S; Ju L; Xi J; He R; Zhao Y; Zhuang R; Huang J
Drug Dev Ind Pharm; 2020 Nov; 46(11):1889-1897. PubMed ID: 32975456
[TBL] [Abstract][Full Text] [Related]
17. [Transport of mPEG-PLGA nanoparticles across the rat nasal mucosa].
Wang JT; Lin DH; Qin LF; Wen Z; Guo GP
Yao Xue Xue Bao; 2013 May; 48(5):752-8. PubMed ID: 23888701
[TBL] [Abstract][Full Text] [Related]
18. Surface modification with polyethylene glycol enhances colorectal distribution and retention of nanoparticles.
Nunes R; Araújo F; Tavares J; Sarmento B; das Neves J
Eur J Pharm Biopharm; 2018 Sep; 130():200-206. PubMed ID: 29960016
[TBL] [Abstract][Full Text] [Related]
19. Poly(vinyl methyl ether/maleic anhydride)-Doped PEG-PLA Nanoparticles for Oral Paclitaxel Delivery To Improve Bioadhesive Efficiency.
Wang Q; Li C; Ren T; Chen S; Ye X; Guo H; He H; Zhang Y; Yin T; Liang XJ; Tang X
Mol Pharm; 2017 Oct; 14(10):3598-3608. PubMed ID: 28892400
[TBL] [Abstract][Full Text] [Related]
20. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.
Bi C; Wang A; Chu Y; Liu S; Mu H; Liu W; Wu Z; Sun K; Li Y
Int J Nanomedicine; 2016; 11():6547-6559. PubMed ID: 27994458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
